rabbit anti sglt2  (Proteintech)

Journal: Frontiers in Immunology

Article Title: Inhibition of the Na + -glucose transporter SGLT2 reduces glucose uptake and IFNγ release from activated human CD4 + T cells

doi: 10.3389/fimmu.2025.1576216

Figure Lengend Snippet: Sodium-glucose co-transporter 2 (SGLT2) is expressed in activated human CD4 + T cell. (A) The cellular metabolic activity of resting and activated cells in presence of GLUT1 inhibitor, WZB 117 or SGLTs inhibitor, phlorizin was normalized to that of activated CD4 + T cells without drug treatment in 5.6 mmol/L or 16.7 mmol/L glucose (N= 4-9). Data are presented as box and whisker plot: box as 25–75 percentiles, whiskers determined with Tukey’s method, black lines in the boxes as median. Statistics: one sample t-test when compared to activated cell group. (B) Relative gene expression levels of facilitated glucose transporters (GLUTs) and Na + -dependent glucose transporters (SGLTs) in activated CD4 + T cells at 5.6 mmol/L glucose (N=7) determined by RNAseq analysis. TPM, transcripts per million. Data represent mean ± SEM. ND, not detected. (C) Representative Western blot image of SGLT2 protein in activated CD4 + T cells in the absence or presence of insulin (INS, 3 nmol/L) at 16.7 mmol/L glucose, HEPG2 cell line and peripheral blood mononuclear cell (PBMC). The stain-free blot image below represents total proteins loaded for each sample. Quantification of SGLT2 band intensity as normalized volume value, which represents each chemiluminescent signal (band) that is properly total protein normalized to the stain-free signal in its corresponding lane (N=3, 16.7 mmol/L glucose). (D) Representative immunofluorescence co-staining of SGLT2 (green) and DAPI (blue) in activated CD4 + T cells in the absence or presence of insulin (INS, 3 nmol/L) at 16.7 mmol/L glucose. Scale bar: 10 µm. N, number of donors.

Article Snippet: Membranes were blocked with EveryBlot blocking buffer (BioRad, 12010020) for 20 min at room temperature (RT) and then incubated overnight at 4°C with a rabbit polyclonal anti-SGLT2 antibody (ProteinTech, 24654-1-AP, 1:500).

Techniques: Activity Assay, Whisker Assay, Gene Expression, Western Blot, Staining, Immunofluorescence

Journal: Frontiers in Immunology

Article Title: Inhibition of the Na + -glucose transporter SGLT2 reduces glucose uptake and IFNγ release from activated human CD4 + T cells

doi: 10.3389/fimmu.2025.1576216

Figure Lengend Snippet: SGLT inhibitors reduce glucose uptake in activated human CD4 + T cell. Glucose uptake in absence or presence of phlorizin ( A , N=7) and SGLT2 selective inhibitor, empagliflozin ( C , N=6) in cells 72 h post-activation, with insulin, in 5.6 mmol/L or 16.7 mmol/L glucose. The changes in percentage of glucose uptake by phlorizin and empagliflozin are shown in (B, D) , respectively. Data are presented as individual values and mean ± SEM. Statistics: two-tailed paired Student’s t-test (A, C) and unpaired Student’s t-test (B, D) . CPM, count per minute. N, number of donors.

Article Snippet: Membranes were blocked with EveryBlot blocking buffer (BioRad, 12010020) for 20 min at room temperature (RT) and then incubated overnight at 4°C with a rabbit polyclonal anti-SGLT2 antibody (ProteinTech, 24654-1-AP, 1:500).

Techniques: Activation Assay, Two Tailed Test

Journal: Frontiers in Immunology

Article Title: Inhibition of the Na + -glucose transporter SGLT2 reduces glucose uptake and IFNγ release from activated human CD4 + T cells

doi: 10.3389/fimmu.2025.1576216

Figure Lengend Snippet: SGLT2 inhibitors and GABA modulate IFNy release in activated human CD4 + T cells. (A, B) IFNγ release from 72 h post-activated cells 72 h post-activation treated with or without phlorizin ( A, N=13), empagliflozin ( B, N=12 at 5.6 mmol/L and N=8 at 16.7 mmol/L glucose) in the absence or presence of insulin, at 5.6 mmol/L or 16.7 mmol/L glucose. (C) IFNγ release from 72 h post-activated cells treated with or without phlorizin or insulin in the presence of GABA (N=10), at 5.6 mmol/L or 16.7 mmol/L glucose. Data are presented as individual values and mean ± SEM. Statistics: Wilcoxon matched-pairs signed rank test. N, number of donors.

Article Snippet: Membranes were blocked with EveryBlot blocking buffer (BioRad, 12010020) for 20 min at room temperature (RT) and then incubated overnight at 4°C with a rabbit polyclonal anti-SGLT2 antibody (ProteinTech, 24654-1-AP, 1:500).

Techniques: Activation Assay

Journal: Frontiers in Immunology

Article Title: Inhibition of the Na + -glucose transporter SGLT2 reduces glucose uptake and IFNγ release from activated human CD4 + T cells

doi: 10.3389/fimmu.2025.1576216

Figure Lengend Snippet: SGLT inhibitor and GABA regulate glycolysis and IFNy release in human CD4 + T cells. Upon activation, human CD4 + T exhibit enhanced glycolysis and increased IFNγ release. Glucose uptake is mediated by not only the facilitated glucose transporters GLUT1/3 but also the sodium-dependent glucose transporter 2 (SGLT2). SGLT inhibitor together with GABA, attenuates glycolysis and reduces IFNγ levels. InR, insulin receptor; IFNG , IFNγ gene. Created in BioRender. Jin, Z. (2025) https://BioRender.com/z20f028 .

Article Snippet: Membranes were blocked with EveryBlot blocking buffer (BioRad, 12010020) for 20 min at room temperature (RT) and then incubated overnight at 4°C with a rabbit polyclonal anti-SGLT2 antibody (ProteinTech, 24654-1-AP, 1:500).

Techniques: Activation Assay

Journal: RSC Advances

Article Title: Synthesis, radiolabeling, and biological evaluation of methyl 6-deoxy-6-[ 18 F]fluoro-4-thio-α- d -maltotrioside as a positron emission tomography bacterial imaging agent †

doi: 10.1039/d5ra00693g

Figure Lengend Snippet: Immunohistochemistry on tissue around the skin pocket. Expression of SGLT1 and SGLT2 in the mock-up area was evaluated by immunohistochemistry. (a) SGLT1 (red) was expressed on fibroblasts (green, vimentin-positive cells), which exhibited an increase in the inflammatory tissue. (b) Similarly, SGLT2 (red) was expressed on fibroblasts (green). The scale bars represent 40 μm.

Article Snippet: To assess cells expressing sodium glucose co-transporter1 (SGLT1) and SGLT2, the samples were stained with rabbit anti-SGLT1 antibody (NBP2-20338, Novus, 1 : 100) or rabbit anti-SGLT2 antibody (GTX59872, GeneTex, 1 : 100).

Techniques: Immunohistochemistry, Expressing

Journal: RSC Advances

Article Title: Synthesis, radiolabeling, and biological evaluation of methyl 6-deoxy-6-[ 18 F]fluoro-4-thio-α- d -maltotrioside as a positron emission tomography bacterial imaging agent †

doi: 10.1039/d5ra00693g

Figure Lengend Snippet: Expression of SGLT1 and SGLT2 in the skin pocket from the control group and from the non-infectious inflammation group was quantified with qPCR. The expression of the target genes is indicated as the ratio to β-actin, a house keeping gene. Expression of SGLT1 in the non-infectious inflammation group was about 12 times that of the control group. Expression of SGLT2 in the non-infectious inflammation group was about 1.8 times the control group.

Article Snippet: To assess cells expressing sodium glucose co-transporter1 (SGLT1) and SGLT2, the samples were stained with rabbit anti-SGLT1 antibody (NBP2-20338, Novus, 1 : 100) or rabbit anti-SGLT2 antibody (GTX59872, GeneTex, 1 : 100).

Techniques: Expressing, Control, Gene Expression

Journal: RSC Advances

Article Title: Synthesis, radiolabeling, and biological evaluation of methyl 6-deoxy-6-[ 18 F]fluoro-4-thio-α- d -maltotrioside as a positron emission tomography bacterial imaging agent †

doi: 10.1039/d5ra00693g

Figure Lengend Snippet: Accumulation of [ 18 F]MFTMT and derivative of [ 18 F]MFTMT by SGLT1. (a) Stable expression of human SGLT1 (hSGLT1) or SGLT2 (hSGLT2) was established in CHO-K1 cells. CHO-K1-hSGLT1 and CHO-K1 hSGLT2 cells internalized 1-NBDG, a specific substrate for SGLT1 and SGLT2. Scale bars represent 100 μm. (b) Retention of [ 18 F]MFTMT and (c) retention of [ 18 F]MFTM by CHO-K1 cells overexpressing SGLTs. CHO-K1-hSGLT1, hSGLT2, and control cells were incubated with 20 μCi mL −1 of [ 18 F]MFTMT for 1 h, and the remaining radioactivity was evaluated. Some cells were treated with vehicle, mizagliflozin, a specific SGLT1 inhibitor, or dapagliflozin, a specific SGLT2 inhibitor. Retention of both [ 18 F]MFTMT and [18F]MFTM in CHO-K1-hSGLT1 cells were significantly higher compared to CHO-K1-hSGLT2 and control cells, and mizagliflozin significantly suppressed the retention of [ 18 F]MFTMT and [ 18 F]MFTM.

Article Snippet: To assess cells expressing sodium glucose co-transporter1 (SGLT1) and SGLT2, the samples were stained with rabbit anti-SGLT1 antibody (NBP2-20338, Novus, 1 : 100) or rabbit anti-SGLT2 antibody (GTX59872, GeneTex, 1 : 100).

Techniques: Expressing, Control, Incubation, Radioactivity

Journal: Molecular therapy. Nucleic acids

Article Title: In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney.

doi: 10.1016/j.omtn.2024.102387

Figure Lengend Snippet: Figure 5. SGLT2-SNA2-ASO suppressed renal SGLT2 expression without severe liver damage SGLT2-SNA2-ASO, SNA-modified control-ASO (cSNA-ASO) or SGLT2-MOE-ASO were subcutaneously administered to mice at doses of 10 mg/kg/day thrice per week for 3 weeks (A) qPCR analysis of SGLT2 expression in the kidneys (n = 8). (B) Serum AST levels (n = 4–8). (C) Serum ALT levels (n = 4–8). (D–G) qPCR analysis for detecting TNF-a (D), TGF-b1 (E), F4/80 (F), and MCP-1 (G) expression in the liver (n = 8). We used 18S as the internal control. (H) Urinary NGAL levels (n = 8). (I) Quantification of CD45 positive area in kidneys (n = 4). (J and K) Representative images and quantification of KIM-1+ area in kidneys (n = 4). Kidney specimens from renal ischemia-reperfusion injury (IRI) were used as a positive control for KIM-1 staining. Scale bar, 500 mm. (L) Serum IL-6 levels (n = 4). Data are presented as the means ± SEMs. #p < 0.05; ##p < 0.01; ###p < 0.001 vs. PBS; *p < 0.05; **p < 0.01; ***p < 0.001; yp < 0.05 by post hoc Tukey’s multiple comparisons after one-way ANOVA, with the exception of the MOE-ASO group.

Article Snippet: Western blotting was performed as described previously.26,27 Immunoblotting was performed by incubating the cells overnight at 4 C with anti-rabbit caspase-3 antibody (1:1,000; Cell Signaling Technology), anti-rabbit cleaved caspase-3 antibody (1:1,000; Cell Signaling Technology), anti-rabbit SGLT2 antibody (1:1,000; Proteintech), anti-mouse b-actin antibody (1:10,000; Sigma).

Techniques: Expressing, Control, Positive Control, Staining